It is critically important to the evolving goals of prostate biopsy to find clinically significant cancer with lethal potential and avoid detection of indolent disease. Better tests and markers are required for improved detection of clinically significant prostate cancer and avoidance of biopsies in men with indolent disease. Currently, there are myriad alternative prostate cancer risk-assessment tests available derived from serum and urine that are designed to improve the specificity for detection of "significant" prostate cancer. Herein we discuss these tests and their clinical implications.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003298 | PMC |
| http://dx.doi.org/10.3909/riu0787 | DOI Listing |
Publication Analysis
Top Keywords
prostate cancer
16
indolent disease
8
prostate
5
cancer
5
differentiating molecular
4
molecular risk
4
risk assessments
4
assessments prostate
4
cancer critically
4
critically evolving
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!